12:00 AM
 | 
Jun 24, 2013
 |  BC Week In Review  |  Company News  |  Other News

Actavis, Lundbeck, Merck KGaA, Ranbaxy, Xellia Pharmaceuticals A/S, Zoetis neurology news

The European Commission fined H. Lundbeck €93.8 million ($125 million) after ruling that deals with four generic companies for Lundbeck's antidepressant Celexa citalopram violated competition law. The commission said that after Lundbeck's basic patents covering Celexa expired, the company only held a number of process patents with more limited protection, which allowed generic versions of the selective serotonin reuptake inhibitor (SSRI) to enter the market. The EC said that Lundbeck then paid...

Read the full 346 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >